TITLE

Evotec gets Milestone as Boehringer Starts Phase I

PUB. DATE
July 2011
SOURCE
Worldwide Biotech;Jul2011, Vol. 23 Issue 7, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Evotec will be given 2 million euros as pharmaceutical company Boehringer Ingelheim starts its Phase I clinical test. The partnership between Evotec and Boehringer seeks to create a compound that fights neuropathic pain, which occurs due to a malfunction or damage to the nervous system. Evotec is a drug research alliance that concentrates on making innovative product methods with major pharmaceuticals including Genentech, Ono, and Boehringer.
ACCESSION #
62132409

 

Related Articles

  • Pharma: Clinic Roundup.  // BioWorld Today;6/21/2012, Vol. 23 Issue 120, p8 

    The article reports on the publication of the design of the RE-ALIGN study, a Phase II trial by Boehringer Ingelheim GmbH of Ingelheim, Germany, at the "American Heart Journal."

  • Pharma: Clinic Roundup.  // BioWorld Today;9/25/2012, Vol. 23 Issue 186, p7 

    The article reports that Boehringer Ingelheim GmbH has completed recruitment for two randomized Phase III trials assessing the efficacy and safety of nintedanib in idiopathic pulmonary fibrosis (IPF).

  • Pegylated Interferon, I Wish I Could Quit You.  // BioWorld Today;10/5/2011, Vol. 22 Issue 193, p3 

    This article reports that Boehringer-Ingelheim GmbH of Ridgefield, Connecticut, will publish results from a planned interim analysis of SOUND-C2, a study evaluating an interferon-free oral combination therapy of BI's investigational compounds, BI 201335, and BI 207127, with and without ribavirin.

  • Evotec receives E4 million milestone payment from Boehringer Ingelheim.  // PharmaWatch: CNS;Oct2011, Vol. 10 Issue 10, p22 

    The article reports on the 4 million euros pre-clinical milestone payment received by Evotec AG from Boehringer Ingelheim GmbH for its discovery alliance.

  • American Diabetes Association.  // BioWorld Today;6/29/2010, Vol. 21 Issue 124, p6 

    The article reports on the data presented by Boehringer Ingelheim GmbH concerning the phase III trials of its dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, which showed that it can lower HbA1c, fasting plasma glucose, postprandial glucose and an adverse event rate similar to placebo.

  • Pharma: Clinic Roundup.  // BioWorld Today;5/22/2012, p7 

    This section offers news briefs on clinical trials, including the impact of the once-daily olodaterol, a beta2-agonist from Boehringer Ingelheim GmbH delivered via the Respimat inhaler on the lung function of patients with chronic obstructive pulmonary disease.

  • Pharma: Clinic Roundup.  // BioWorld Today;9/13/2012, Vol. 23 Issue 178, p9 

    The article reports on the results presented by Boehringer Ingelheim GmbH of a subanalysis from the RE-LY trial at the Asia Pacific Stroke Conference in Japan confirming the benefits offered by Pradaxa (dabigatran etexilate) for the management of patients with atrial fibrillation in Asia.

  • American College of Cardiology.  // BioWorld Today;4/5/2011, Vol. 22 Issue 65, p4 

    The article focuses on the results of a retrospective subanalyses by Boehringer Ingelheim GmbH of a trial of dabigratran etexilate mesylate capsules.

  • Pharma: Clinic Roundup.  // BioWorld Today;8/16/2013, Vol. 24 Issue 157, p10 

    The article announces the completion of enrollment of treatment-naive genotype-1b patients for the Phase III interferon-free HCVerso 1 and 2 drug trials of drug maker Boehringer Ingelheim GmbH, along with publication in "The Lancet" of test data on the company's diabetes drug linagliptin.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics